1. Home
  2. Directory
  3. Washington
  4. Seattle
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1376662049

DARRYL S WELLS MD
Prescription History 1376662049
Internal Medicine - Clinical Cardiac Electrophysiology in Seattle, WA


Quality Rating: 79.99 out of 100 score

NPI Status: Active since March 27, 2007

Contact Information

550 17TH AVE
SUITE 680
SEATTLE, WA
ZIP 98122
Phone: (206) 861-8550

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DARRYL S WELLS MD, an active Clinical Cardiac Electrophysiology specialist practicing in Seattle, WA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 51 documented patient claims. Among these therapy options, the most frequently utilized medication is Xarelto, which accounts for 21 claims alone.

Medication Index

F
M
X
No matching medications currently found on file.

Flecainide Acetate

Generic Formulation: Flecainide AcetateSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.0
Days Supply 450
WA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills92.6
Peer Average Days Supply2,754
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $177.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.62

State Avg Cost Per Claim

$70.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.

Therapeutic Applications

This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as sustained ventricular tachycardia and paroxysmal supraventricular tachycardia). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. It is also used to prevent certain types of irregular heartbeat from returning (such as atrial fibrillation). Flecainide is known as an anti-arrhythmic drug. It works by blocking certain electrical signals in the heart that can cause an irregular heartbeat. Treating an irregular heartbeat can decrease the risk for blood clots, and this effect can reduce your risk of heart attack or stroke. Older adults should discuss the risks and benefits of this medication with their doctor or pharmacist, as well as other effective and possibly safer treatments.

Metoprolol Succinate

Generic Formulation: Metoprolol SuccinateSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 17
30-Day Fills 45.0
Days Supply 1,350
WA State Average Benchmarks
Peer Average Claims82.0
Peer Average 30-Day Fills200.2
Peer Average Days Supply5,961
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.3% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $408.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.01

State Avg Cost Per Claim

$22.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Therapeutic Applications

This medication is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Clinical Cardiac Electrophysiology
Provider Metrics Summary
Total Claims 21
30-Day Fills 33.0
Days Supply 990
WA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills71.1
Peer Average Days Supply2,054
Conservative Utilization

This provider writes prescriptions for this formulation 44.7% less frequently than the standard regional baseline metric for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,267.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$869.87

State Avg Cost Per Claim

$955.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DARRYL S WELLS MD provides transparency into local medical care patterns within Seattle, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Clinical Cardiac Electrophysiology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.